EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open‐Label Trial

Ramesh R. Boinpally, Joel M. Trugman

Clinical and Translational Science · 2026-04 · 19 (4)

DOI: 10.1111/cts.70560 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Ubrogepant (Ubrelvy), a CGRP receptor antagonist, is approved for acute treatment of migraine with or without aura in adults. Because ubrogepant treats a neurological condition, it is of interest to know central nervous system exposure. Ubrogepant concentrations in plasma and cerebrospinal fluid (CSF) were measured in participants with a history of migraine. This analysis included a subset of participants with a ≥ 1 year history of migraine who were enrolled in a Phase 1b multi‐center, open‐label trial and who underwent a single CSF collection via lumbar puncture. All participants received a single oral dose of 100 mg ubrogepant. Plasma and CSF ubrogepant concentrations were measured using LC–MS/MS at pre‐defined post‐dose timepoints (plasma: 0–24 h; CSF: 2 or 4 h). Ubrogepant CSF/plasma concentration ratios at 2 and 4 h were determined. Ubrogepant safety and tolerability were evaluated through reporting of treatment‐emergent adverse events (TEAEs; ≤ 30‐days after dosing), physical examination, ECG, laboratory testing, and vital sign monitoring. A total of 8 participants were included. Mean (±SD) age was 34.5 ± 9.58 years and 4 participants (50%) were male. At 2 h, mean (±SD) CSF and plasma ubrogepant concentrations were 1.1 ± 0.8 and 354 ± 163 ng/mL, respectively (CSF/plasma ratio: 0.36% ± 0.29%); at 4 h, 2.3 ± 1.9 and 218 ± 84 ng/mL, respectively (CSF/plasma ratio: 0.94% ± 0.64%). No serious TEAEs, deaths, or significant changes in laboratory values, vital signs, or ECGs occurred. Because ubrogepant half maximal effective concentration (EC 50 ) has been estimated at ~1.4 ng/mL, ubrogepant could act both centrally and peripherally to relieve migraine symptoms. ClinicalTrials.gov , NCT04179474 (registration date: 27 November 2019).

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →